Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02473510 · ClinicalTrials.gov registry record · Phase 4

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

A Phase 4 study of Healthy and Influenza, sponsored by MedImmune.

Completed
Registry status
Phase 4
Development phase
301
Enrollment target
3
Study locations

NCT02473510: Completed Phase 4 study of Healthy and Influenza, sponsored by MedImmune.

NCT02473510 is a Phase 4 study of Healthy and Influenza that has completed, run by MedImmune. The registered enrollment target is 301 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02473510, a Phase 4 study of Healthy and Influenza, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 4
Development phase
301 participants
Enrollment target
3
Study locations

Study Summary

This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season

Primary Outcome

Percentage of participants with fever defined as oral temperature \>=101 degrees F were reported.

Conditions Studied

Interventions

  • OTHER Placebo
  • BIOLOGICAL Trivalent Influenza Vaccine

Study Locations (3)

Florida

  • Research Site - South Miami

Georgia

  • Research Site - Stockbridge

Oregon

  • Research Site - Portland

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2015-06
Est. Completion 2016-01
Phase Phase 4
MedImmune

210 total trials

What the finished NCT02473510 record still lists

NCT02473510 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (53% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02473510 reports a single indexed study location in Florida, Georgia, Oregon.

Frequently Asked Questions

What is clinical trial NCT02473510 about?

NCT02473510 is a clinical study titled "Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season". This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season

What is the current status of trial NCT02473510?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 301 participants. The study started on 2015-06. Estimated completion is 2016-01.

What conditions does trial NCT02473510 study?

This clinical trial studies the following conditions: Healthy, Influenza.

What interventions are being tested in trial NCT02473510?

The interventions under investigation include: Placebo (OTHER), Trivalent Influenza Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT02473510?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02473510 being conducted?

This trial has 3 study locations across Florida, Georgia, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02473510's enrollment target sits among peer trials

301 75th of 1090 higher than 1,015 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05005975 · 301 participants · Phase 3

    Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

  • NCT05722561 · 302 participants · Phase 2

    E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

  • NCT06015737 · 302 participants · Phase 3

    A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

  • NCT07176273 · 302 participants · NA

    Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02473510, the US trial registry maintained by the National Library of Medicine. NCT02473510 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.